Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Patent
1993-06-09
1996-04-30
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
424 46, 514851, A61K 912
Patent
active
055122698
ABSTRACT:
A method of facilitating the clearance of retained pulmonary secretions in a subject using lantibiotics is disclosed. The method comprises administering to the lungs of the subject an effective amount of a lantibiotic. The lantibiotic is preferably administered by topically applying it to the respiratory epithelia, such as by generating an aerosol thereof which is then inhaled by the subject. A preferred lantibiotic for carrying out the present invention is duramycin. The method may be used in treating disorders such as cystic fibrosis, chronic bronchitis, and asthma. Also disclosed is a method of combatting tuberculosis comprising administering a lantibiotic to a subject in need of such treatment.
REFERENCES:
patent: 4501729 (1985-02-01), Boucher et al.
patent: 5162348 (1992-11-01), Glass
patent: 5292498 (1994-03-01), Boucher, Jr.
R. Boucher, Drug Therapy in the 1990s-What Can We Expect for Cystic Fibrosis?, DRUGS, vol. 43, pp. 431-439 (1992).
CA 108(15): 128373q, (1988).
Malabarba A. et al., Synthesis and biological activity of some amide derivatives of the lantibiotic actagardine, the Journal of Antibiotics, vol. XLIII, No. 9, pp. 1089-1097, (1990).
J. M. Little Wood et al., Aerosol antibiotic treatment in cystic fibrosis, Arch. Dis. Child (Eng) 68,(6) pp. 788-792 (Jun. 1993).
J. A. Bosso, Advances in the pharmacotherapy of cystic fibrosis, Journal of Clinical Pharmacy and Therapeutics, 17, pp. 263-270 (1992).
R. Zabner and J. P. Quinn, Antimicrobials in Cystic Fibrosis: Emergence of Resistance and Implications for Treatment, Seminars in Respiratory Inflections 7, pp. 210-217 (Sep. 1992).
I. MacLusky et al., Inhaled Antobiotics in Cystic Fibrosis: Is There a Therapeutic Effect?, The Journal of Pediatrics, vol. 108, pp. 861-865, (May 1986).
M. A. Wall et al., Inhaled Antibiotics in Cystic Fibrosis, The Lancet, p. 1325, (Jun. 1983).
C. Stock, Breathing Easier, Endeavors X, 10-12 (1992).
D. Stone et al. Inhibition of Clathrin-coated Vesicle Acidification by Duramycin J. Biol. Chem., 259, 2701-2703 (1984).
M. M. Cloutier et al., Duramycin Enhances Chloride Change Activity in Cystic Fibrosis Nasal Epithelial Cells Pediatric Pulmonology Support 2, (1988).
M. M. Cloutier et al., Stimulation of Chloride Secretion by Duramycin Pediatric Pulmonology Supplement 1, 112 (1987).
L. Guernsey et al., Duramycin Increases Intracellular Calcium Pediatr. Pulmonol. 4: Suppl., p. 116 (1989).
M. M. Cloutier et al,. Duramycin Enhances Chloride Secretion in Airway Epithelium The American Physiological Society C450-453 (1990).
M. Roberts et al., Stimulation of Sodium Transport by Duramycin in Cultured Human Colonic Epithelia The Journal of Pharmacology & Experimental Therapeutics 259, 1050-1058 (1991).
G. J. Annas, Control of Tuberculosis-The Law and the Public's Health Legal Issues in Medicine 328, 585-588 (1993).
T. R. Frieden et al., The Emergence of Drug-Resistant Tuberculosis in New York City The New England Journal of Medicine 328, 521-532 (1993).
M. Barinaga, New Test Catches Drug-Resistant TB in the Spotlight Science 260, 750 (1993).
W. R. Jacobs, Jr. et al., Rapid Assessment of Drug Susceptibilities of Mycobacterium tuberculosis by Means of Luciferase Reporter Phages Science 260, 819-822 (1993).
A. T. R. Mattick and A. Hirsch, Further Observations on an Inhibitory Substance (NISIN) From Lactic Streptococci The Lancet (ii), 5-7 (Jul. 5, 1947.
A. C. Frazer et al., The Biological Effects of Food Additives I.-Nisin J. Sci. Food Agric. 13 pp. 33 & 42; (Jan. 1962).
A. Hurst, Nisin Advances in Applied Microbiology 27, (pp. 85, 94-95) (1981).
G. Jung, Lantibiotics-Ribosomally Synthesized Biologically Active Polypeptides containing Sulfide Bridges and .alpha.,.beta.-Didehydroamino Acids, Agnew. Chem. Int. Ed. Engl. 30 1051-1078 (1991).
F. Hayashi et al., The Structure of PA48009: The Revised Structure of Duramycin The Journal of Antibiotics XLIII, No. II p. 1421 (1990).
A. Fredenhagen et al., Duramycins B and C, Two New Lanthionine Containing Antibiotics As Inhibitors Of Phospholipase A.sub.2 The Journal of Antibiotics XLIII, No. II pp. 1403-1412 (1990).
Boucher, Jr. Richard C.
Henke David C.
Molina y Vedia Luis M.
Stutts Monroe J.
Bawa Raj
Burroughs Wellcome Co.
Page Thurman K.
University of North Carolina at Chapel Hill
LandOfFree
Method of treating retained pulmonary secretions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating retained pulmonary secretions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating retained pulmonary secretions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-626505